Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SPRY domain-containing protein 4 (SPRYD4)
- Target
- SPRYD4
- Molecular classification
- SPRY domain-containing protein, Other (potentially E3 ubiquitin-protein ligase family association[4][5])
01
Overview
SPRY domain-containing protein 4 (SPRYD4) is a nuclear protein characterized by the presence of a SPRY domain, which mediates protein–protein interactions in diverse biological processes[1]. SPRYD4 is expressed ubiquitously, with higher expression in tissues such as kidney, bladder, brain, thymus, and stomach. Functional studies indicate that SPRYD4 acts as a tumor suppressor: its expression is frequently downregulated in certain cancers, including hepatocellular carcinoma and cholangiocarcinoma, where lower levels are associated with poor prognosis and aggressive disease. Overexpression of SPRYD4 in experimental models inhibits cancer cell proliferation, promotes cell cycle arrest, and induces apoptosis. Additionally, SPRYD4 may modulate immune cell infiltration and immune checkpoint pathways in tumors, suggesting roles in immune response regulation and possible utility as both a prognostic biomarker and therapeutic target[1][2].
- Other names
- SPRYD4DKFZp686N0877SPRY domain containing 4
02
Biological functions
Protein–protein interactionsNuclear regulatory functionTumor suppressionRegulation of cell proliferation and apoptosis[1][2]
03
Disease associations
Cancer (Tumor suppressor in hepatocellular carcinoma and cholangiocarcinoma)[1][2]
04
Biomarkers
Prognostic marker for hepatocellular carcinoma (HCC) and cholangiocarcinoma: lower expression linked to poor prognosis[1][2]
Beyond the preview
Go deeper on SPRY domain-containing protein 4 (SPRYD4).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPRY domain-containing protein 4 (SPRYD4).